Primary central nervous system lymphoma in a patient treated with natalizumab
- 1 September 2009
- journal article
- case report
- Published by Wiley in Annals of Neurology
- Vol. 66 (3), 403-406
- https://doi.org/10.1002/ana.21782
Abstract
A 40‐year‐old man with relapsing‐remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th decade of life. Immunodeficiency, iatrogenic immunosuppression, and some autoimmune diseases are known as predisposing conditions, and in these patients PCNSL peaks in the 4th decade. Because there is no increased prevalence of PCNSL in MS, and the patient was otherwise not immunocompromised, an association between natalizumab therapy and PCNSL cannot be ruled out. Ann Neurol 2009;66:403–406This publication has 23 references indexed in Scilit:
- Primary CNS Lymphoma in Immunocompetent PatientsThe Oncologist, 2009
- Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: A pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphomaAnnals of Neurology, 2008
- Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE TrialGastroenterology, 2007
- Cancer immunoediting from immune surveillance to immune escapeImmunology, 2007
- Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory DiseasesCNS Drug Reviews, 2007
- Primary CNS lymphomaNature Clinical Practice Neurology, 2007
- Primary CNS LymphomaJournal of Clinical Oncology, 2006
- Epileptic seizures in multiple sclerosis: clinical and EEG correlationsNeurological Sciences, 2003
- Primary intracerebral malignant lymphoma: report of 248 casesJournal of Neurosurgery, 2000
- Epstein-Barr virus in AIDS-related primary central nervous system lymphomaThe Lancet, 1991